Comparison of the effects of rosuvastatin monotherapy and atorvastatin-ezetimibe combined therapy on the structure of erythrocyte membranes in patients with coronary artery disease

Pharmacological Reports : PR
Małgorzata Olszewska-BanaszczykMarlena Broncel

Abstract

Abnormalities in the physical properties of the red blood cells (RBCs) membranes may underlie the defects that are strongly linked to cardiovascular diseases (CVD). The aim of the study was to compare the effects of two therapies of equal hipolipemic efficacy on the erythrocyte membrane fluidity, concentration of membrane cholesterol, lipids peroxidation and RBCs distribution witdh in patients with CVD. The study included 44 patients with angiographic evidence of CVD, who despite previous 6-month hypolipemic therapy, did not achieve the concentration of LDL-C <70mg/dl. They were randomly assigned to: rosuvastatin 20mg/day (R20) and atorvastatin 10mg/day combined with ezetimibe 10mg/day (A10+E10). The membrane fluidity, the concentration of thiobarbituric acid reactive substances -TBARS, concentration of membrane cholesterol were evaluated after 6 months therapy. An improvement in lipid parameters was observed in each of the groups studied. In R20 the treatment resulted in 33% reduction concentrations of TBARS in serum, as well as in a decrease in membrane cholesterol by 16%, fluorescence anisotropy of TMA-DPH by 17.7%, fluorescence anisotropy of DPH by 2.8%. In A10+E10 the reduction of TBARS by 20.5% in serum, membrane choleste...Continue Reading

References

Dec 15, 1978·Biochimica Et Biophysica Acta·M Shinitzky, Y Barenholz
Jan 1, 1971·British Journal of Haematology·J Stocks, T L Dormandy
Mar 7, 2003·American Journal of Hypertension·Kazushi Tsuda, Ichiro Nishio
Jan 1, 1963·Archives of Biochemistry and Biophysics·J T DODGED J HANAHAN
Dec 4, 2003·The International Journal of Biochemistry & Cell Biology·Maria KoterJulita Chojnowska-Jezierska
Dec 12, 2003·The New England Journal of Medicine·Frank D KolodgieRenu Virmani
Apr 4, 2007·Pathophysiology : the Official Journal of the International Society for Pathophysiology·O G LunevaE I Chazov
Nov 24, 2007·Biochimica Et Biophysica Acta·Sangeeta AdakMaitree Bhattacharyya
Jan 4, 2008·Circulation·Marcello TonelliUNKNOWN for the Cholesterol and Recurrent Events (CARE) Trial Investigators
Sep 17, 2009·Journal of Cellular and Molecular Medicine·Jian-Ming LüChangyi Chen
Feb 8, 2011·Journal of Cardiovascular Pharmacology·Robert Krysiak, Boguslaw Okopien
Aug 11, 2012·Advances in Experimental Medicine and Biology·Kushang V PatelJoseph M Rifkind
Mar 1, 2013·Clinical Hemorheology and Microcirculation·A TothK Toth
Sep 10, 2013·Journal of cardiology·Ibrahim AkpinarIbrahim Celal Haznedaroglu
Aug 28, 2016·European Heart Journal·Alberico L CatapanoUNKNOWN ESC Scientific Document Group

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.